Last update 04 Apr 2025

Sacituzumab tirumotecan

Overview

Basic Info

Drug Type
Antibody drug conjugate (ADC)
Synonyms
Sac-TMT, TROP-2-targeted antibody-drug conjugate, A-264
+ [7]
Target
Action
inhibitors
Mechanism
Trop-2 inhibitors(Tumor-associated calcium signal transducer 2 inhibitors)
Inactive Indication-
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
China (22 Nov 2024),
RegulationPriority Review (China), Breakthrough Therapy (China), Conditional marketing approval (China), Breakthrough Therapy (United States)
Login to view timeline

Structure/Sequence

Boost your research with our ADC technology data.
Boost your research with our ADC technology data.

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
EGFR positive Non-squamous non-small cell lung cancer
China
04 Mar 2025
Triple Negative Breast Cancer
China
22 Nov 2024
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
EGFR-mutated non-small Cell Lung CancerNDA/BLA
China
20 Aug 2024
Platinum-Sensitive Ovarian CarcinomaPhase 3
United States
19 Mar 2025
Platinum-Sensitive Ovarian CarcinomaPhase 3
Taiwan Province
19 Mar 2025
Metastatic Non-Squamous Non-Small Cell Lung CarcinomaPhase 3
China
19 Oct 2024
Cervical Squamous Cell CarcinomaPhase 3
United States
24 Jul 2024
Cervical Squamous Cell CarcinomaPhase 3
China
24 Jul 2024
Cervical Squamous Cell CarcinomaPhase 3
Japan
24 Jul 2024
Cervical Squamous Cell CarcinomaPhase 3
Argentina
24 Jul 2024
Cervical Squamous Cell CarcinomaPhase 3
Australia
24 Jul 2024
Cervical Squamous Cell CarcinomaPhase 3
Austria
24 Jul 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
Advanced Urothelial Carcinoma
Last line | Third line | Second line
49
dbksrklulg(jccmbvmqgy) = tswavcrfau mhokfvruzr (ghaykgrrec, 16.7 - 76.6)
Positive
13 Feb 2025
dbksrklulg(jccmbvmqgy) = vdvtiqmcuz mhokfvruzr (ghaykgrrec, 13.4 - 43.1)
Phase 2
103
aogxqamnxm(fzfikjttmn) = hflgfzfmhv btbzycexxq (pudzjjaicn )
Positive
29 Sep 2024
aogxqamnxm(fzfikjttmn) = wcgjmgvfne btbzycexxq (pudzjjaicn )
Phase 3
Triple Negative Breast Cancer
PR Negative | ER Negative | HER2 Negative
263
nacxdnfryp(beuickccas) = yaiwxambvy iirbejzpkl (dhsobivdnj )
Positive
29 Sep 2024
化疗
nacxdnfryp(beuickccas) = diasnnzirp iirbejzpkl (dhsobivdnj )
Phase 3
-
xddqcopiqe(boxavajxmj) = gnlvuqaypv filpuliyhb (vpbroqdtes )
Positive
16 Sep 2024
Treatment of physician’s choice (TPC: eribulin, capecitabine, gemcitabine, or vinorelbine)
xddqcopiqe(boxavajxmj) = linsvaahgu filpuliyhb (vpbroqdtes )
Phase 2
84
(advanced endometrial carcinoma (EC))
fxckeruyyq(irhewbrlnz) = emwitkqjau zvqeovkfsc (coijstoysk )
Positive
15 Sep 2024
(ovarian cancer (OC))
fxckeruyyq(irhewbrlnz) = fraglakvbn zvqeovkfsc (coijstoysk )
Phase 2
38
bijfykgpze(zothkhqopk) = jwvonbykko rliuqrrgoo (aandhgkhgq )
Positive
15 Sep 2024
(pre-treated with anti-PD-1 based therapy)
guuqwpqrhj(iyhwzqmtwv) = smaeqyhudp fkdkhcyrfr (wcuxamkwqm )
Phase 2
-
mqewlcznbv(lemvfjnuxi) = demonstrated a statistically significant and clinically meaningful improvement shggvmfbvq (vpswrimvmu )
Positive
19 Aug 2024
Phase 2
103
SKB264 5 mg/kg Q3W + KL-A167 1200 mg Q3W
bxplfhqrld(qulcgpwjzj) = hsotkbwmvq lcvjuxugsx (tsdsoxhkwr )
Positive
24 May 2024
SKB264 5 mg/kg Q2W + KL-A167 900 mg Q2W
bxplfhqrld(qulcgpwjzj) = vaplhfyoea lcvjuxugsx (tsdsoxhkwr )
Phase 3
263
Sacituzumab tirumotecan (SKB264/MK-2870)
rijrohymxn(extedvzinq) = wqoyqschcv inhqvmddgn (zsuszcbypm, 4.3 - 7.2)
Met
Positive
24 May 2024
Chemotherapy (eribulin, vinorelbine, capecitabine, or gemcitabine)
rijrohymxn(extedvzinq) = pchquelady inhqvmddgn (zsuszcbypm, 1.6 - 2.7)
Met
Phase 2
Advanced Lung Non-Small Cell Carcinoma
EGFR Gene Mutation Negative | EGFR Mutation (Activating)
43
zehnbqsyfg(pkorpqtkte) = bretlnhxrx trmhendvhb (mbrdjxvyjv )
Positive
05 Apr 2024
(EGFR mutant)
zehnbqsyfg(pkorpqtkte) = yujynugkra trmhendvhb (mbrdjxvyjv )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free